1st Quarter - Report
JAZZ PHARMACEUTICALS, INC. for JAZZ PHARMACEUTICALS, INC.
Client
Income
—
Expenses
$630,000
Expense method
A: Lobbying Disclosure Act definitions
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 1st Quarter - Report | Apr 20, 2023 | $630,000 | Replaced |
| 1st Quarter - Report (this page) | Apr 20, 2023 | $630,000 | Yes |
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Pharmacy PHA
Issues related to the regulation of cannabis and CBD Research and development of cannabis-derived therapies Provisions related to patient safety, CBD product regulations and FDA regulation and enforcement Drug safety, prescription drug abuse and drug pricing
| Lobbyist | Covered position, as disclosed |
|---|---|
| KARAS GROSS | — |
| VIRGINIA MCMILLIN | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.